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Abstract 48 
 49 
Background: Circulating blood lipids cause coronary heart disease (CHD). However, the 50 
precise way in which one or more lipoprotein lipid-related entities account for this 51 
relationship remains unclear. We sought to explore the causal relationships of blood 52 
lipid traits with risk of CHD using multivariable Mendelian randomization. 53 
 54 
Methods: We conducted GWAS of circulating blood lipid traits in UK Biobank (up to 55 
n=440,546) for LDL cholesterol, triglycerides and apolipoprotein B to identify lipid-56 
associated SNPs. Using data from CARDIoGRAMplusC4D for CHD (consisting of 60,801 57 
cases and 123,504 controls), we performed univariable and multivariable Mendelian 58 
randomization (MR) analyses. Similar analyses were conducted for HDL cholesterol and 59 
apolipoprotein A-I. 60 
 61 
Findings: GWAS identified multiple independent SNPs associated at P<5x10-8 for LDL 62 
cholesterol (220), apolipoprotein B (n=255), triglycerides (440), HDL cholesterol (534) 63 
and apolipoprotein AI (440). Between 56-93% of SNPs identified for each lipid trait had 64 
not been previously reported in large-scale GWAS. Almost half (46%) of these SNPs were 65 
associated at P<5x10-8 with more than one lipid related trait. Assessed individually using 66 
MR, each of LDL cholesterol (OR 1.66 per 1 standard deviation higher trait; 95%CI: 1.49; 67 
1.86; P=2.4x10-19), triglycerides (OR 1.34; 95%CI: 1.25, 1.44; P=9.1x10-16) and 68 
apolipoprotein B (OR 1.73; 95%CI: 1.56, 1.91; P=1.5x10-25) had effect estimates 69 
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consistent with a higher risk of CHD. In multivariable MR, only apolipoprotein B (OR 70 
1.92; 95%CI: 1.31, 2.81; P=7.5x10-4) retained a robust effect with the estimate for LDL 71 
cholesterol (OR 0.85; 95%CI: 0.57; 1.27; P=0.44) reversing and that of triglycerides (OR 72 
1.12; 95%CI: 1.02, 1.23; P=0.01) becoming markedly weaker. 73 
Individual MR analyses showed a 1-SD higher HDL-C (OR 0.80; 95%CI: 0.75, 0.86; 74 
P=1.7x10-10) and apolipoprotein A-I (OR 0.83; 95%CI: 0.77, 0.89; P=1.0x10-6) to lower the 75 
risk of CHD but these effect estimates weakened to include the null on accounting for 76 
apolipoprotein B. 77 
 78 
Conclusions: Apolipoprotein B is of fundamental causal relevance in the aetiology of 79 
CHD, and underlies the relationship of LDL cholesterol and triglycerides with CHD. 80 
81 
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Introduction 82 
 83 
There is incontrovertible evidence that lipids play a causal role in the aetiology of 84 
coronary heart disease (CHD) [1-3]. Multiple large-scale randomized trials of lipid 85 
modifying therapies have conclusively shown that lowering of cholesterol in atherogenic 86 
lipoproteins leads to a reduction in risk of CHD[4, 5]. These findings have been 87 
recapitulated in human genetic studies using genetic variants robustly associated with 88 
low-density lipoprotein (LDL) cholesterol [6-9]. 89 
 90 
Each circulating atherogenic lipoprotein particle includes one apolipoprotein B particle 91 
but the amount of cholesterol (especially in LDL particles) and the amount of 92 
triglycerides (especially in very low-density lipoprotein particles) can vary extensively 93 
between lipoprotein particles[10]. Thus, while the concentration of LDL cholesterol and 94 
triglycerides quantifies the concentration of these lipid substances in the blood, they do 95 
not precisely quantify the number of atherogenic lipoproteins; in contrast, the 96 
concentration of apolipoprotein B particles is directly proportional to the number of 97 
circulating atherogenic particles in the blood. Evidence from human genetics supports a 98 
causal role of LDL cholesterol, triglycerides and apolipoprotein B in CHD[11-13]. While it 99 
is plausible that each lipid-related entity does individually play a causal role, it is also 100 
feasible that one trait predominates. Elucidating the comparative role of blood lipids in 101 
the aetiology of CHD has important repercussions not only in terms of a clearer 102 
understanding of the underlying pathophysiology, but also in terms of which 103 
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biomarker(s) should be the focus of lipid-modifying therapeutics and might have more 104 
application in the clinical setting.  105 
 106 
Disentangling the relationships of atherogenic lipoprotein lipids and risk of CHD is non-107 
trivial, given the correlated nature of these traits. One such approach is to take genetic 108 
variants that associate with more than one lipid trait and scale the CHD associations for 109 
a given difference in lipid, in an attempt to identify which one or more traits appears to 110 
have a consistent effect on risk of CHD. However, such an approach makes use of 111 
indirect extrapolations and might be liable to biases, such as differential measurement 112 
error in the lipid traits. Another approach is to use Mendelian randomization (MR), a 113 
genetic approach that can facilitate an assessment of causality under certain 114 
assumptions.[14] Conventionally, MR involves the analysis of individual exposure to 115 
outcome relationships. A recently-developed extension to MR, so-called multivariable 116 
MR, permits the appraisal of multiple risk factors simultaneously. By including the 117 
genetic associations for multiple exposures in the same model, multivariable MR can 118 
elucidate which traits retain a causal relationship with an outcome of interest, through 119 
the genetic interrogation of potential confounders[15]. 120 
 121 
In this study, we sought to use human genetics to disentangle which one or more of the 122 
atherogenic lipid-related traits (apolipoprotein B, LDL cholesterol and triglycerides) is 123 
the underlying causal risk factor for CHD. We first conducted de novo GWAS of lipid-124 
related traits using the UK Biobank to identify variants robustly associated with each 125 
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trait. We then conducted MR analyses, including multivariable MR, to elucidate which of 126 
the atherogenic lipid traits cause CHD. Finally, we investigated whether the entity 127 
underlying the causal role of atherogenic lipid-related traits in CHD also accounted for 128 
the ‘cardioprotective’ association of HDL related phenotypes. 129 
130 
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Methods 131 
 132 
Data sources 133 
We used data from the UK Biobank (UKBB) under application #15825 and summary 134 
estimates from CARDIoGRAMplusC4D [16]. All individual participant data used in this 135 
study were obtained from the UK Biobank study who have obtained ethics approval 136 
from the Research Ethics Committee (REC - approval number: 11/NW/0382). All 137 
participants enrolled in UK Biobank have signed consent forms. 138 
 139 
Data handling 140 
Lipid-related traits in the UK Biobank were standardized/normalized using inverse rank-141 
normalization such that the mean was 0 and standard deviation was 1, allowing 142 
comparison of effect estimates between traits.  143 
 144 
GWAS of lipid-related traits 145 
We identified SNPs associated with each of the lipid-related traits using the BOLT-LMM 146 
software[17]. Analyses were adjusted for age, sex and a binary variable denoting the 147 
genotyping chip individuals were allocated to in UKBB. Population stratification and 148 
relatedness was accounted for using a mixed model after excluding individuals of non-149 
European descent based on k-means clustering (k=4). Further details on genotyping 150 
quality control, phasing, imputation and association testing have been reported 151 
previously[18, 19]. We assigned a SNP as associated with a lipid-related trait of interest 152 
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through use of a conventional GWAS threshold (P<5x10-8) and SNPs were binned into 153 
loci based on pair-wise LD (r2<0.001), with the SNP with the strongest association with 154 
the trait of interest (as defined by P value) being retained in each locus. We defined 155 
novel SNPs as those associated with the trait of interest at P<5x10-8 in our analyses 156 
where an association had not been previously reported at P<5x10-8, within 1MB and at 157 
r2<0.001, by the Global Lipids Genetics Consortium[20] (for LDL cholesterol, 158 
triglycerides and HDL cholesterol) or by Kettunen et al[21] (for apolipoprotein B or 159 
apolipoprotein A-I). 160 
 161 
Synthesis and characterization of genetic instruments 162 
SNPs associating with lipid related traits at conventional GWAS thresholds (P<5x10-8) 163 
were taken forward to generate genetic instruments for each phenotype. We 164 
characterized the genetic instruments in several ways. First, to characterize the 165 
‘specificity’ of individual SNPs included in each genetic instrument, we elucidated how 166 
many SNPs associated with traits other than the primary lipid trait of interest at 167 
conventional GWAS thresholds of significance (P<5x10-8) and used this information to 168 
generate a Venn diagram. Second, we characterize instrument ‘specificity’ by taking per-169 
allele SNP estimates from our GWAS for each lipid trait and conducting inverse variance 170 
weighted regressions on these summary estimates to elucidate the association of 171 
genetic instruments across the various lipid related traits – these estimates are 172 
presented as standardized differences per 1-standard deviation (SD) higher genetically-173 
predicted trait. While we recognize that this approach may be prone to inflation, the 174 
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primary motivation is to characterize the associations of lipid instruments with the lipid-175 
related traits: we do not interpret these as formal instrumental variable estimates. 176 
 177 
Genetic analyses to elucidate causality 178 
We first conducted univariable Mendelian randomization (MR) analyses for each lipid-179 
related trait. For this, we harmonized SNPs identified from our GWASs of blood lipids in 180 
UK Biobank to those SNPs available in CARDIoGRAMplusC4D by either matching the SNP 181 
directly, or by selecting proxy SNPs in high linkage disequilibrium (r2>0.8). This led to a 182 
small drop in the number of SNPs being available for MR, with a median of 93% SNPs 183 
identified in GWAS available for MR (the numbers available for each trait are provided in 184 
Table 1).  We used the inverse variance weighted approach which, in brief takes the 185 
form of a linear regression of the SNP-outcome association regressed on the SNP-186 
exposure association weighted by the inverse of the square of the standard error of the 187 
SNP-outcome association, with the intercept constrained at the origin. We additionally 188 
conducted univariable MR analyses using weighted median [22], weighted mode [23] 189 
and MR-Egger [24] approaches.  190 
 191 
We next conducted multivariable MR, which is a statistical approach that allows for the 192 
association of SNPs with multiple phenotypes to be incorporated into the analysis  193 
permitting an estimation of the direct effect of each phenotype on the outcome(i.e. an 194 
effect which is not mediated by any other factor in the model[15]) see Supplementary 195 
Figure 1 for further details. In this manuscript, we use the term 'adjusted' in the context 196 
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of multivariable MR to mean 'direct' effects, i.e. the effect of a lipid trait on CHD while 197 
accounting for either mediation or confounding by another trait included in the model. 198 
For the multivariable MR analyses, we fitted a model with apolipoprotein B, LDL 199 
cholesterol and triglycerides to identify which one or more traits was responsible for the 200 
effect of “atherogenic” lipid-related traits on risk of CHD. We then took the atherogenic 201 
trait(s) that retained an effect on CHD in the multivariable MR model forward and 202 
further adjusted for apolipoprotein A-I and HDL cholesterol to assess the causal effect of 203 
HDL-related phenotypes with risk of CHD. In the setting of multivariable MR, we 204 
included all GWAS associated SNPs for all traits in the model. This meant that there 205 
were differing numbers of SNPs in the two multivariable models tested. 206 
 207 
We characterized instrument strengths in both the univariable and multivariable MR 208 
settings, as follows: for the univariable estimates, we generated the mean F-statistic, 209 
using the approximation described by Bowden et al[25]. For the multivariable estimate, 210 
we generated the conditional F-statistic [26]. 211 
 212 
Software 213 
The BOLT-LMM software was used to undertake GWAS [17]. MR analyses were 214 
conducted using the ‘TwoSampleMR’ R package[27]. Manhattan plots were generated 215 
using the ‘ggplot2’ package[28].The Venn diagram was generated using the online tool 216 
available at http://bioinformatics.psb.ugent.be/webtools/Venn [accessed 13th August 217 
2019]. 218 
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 219 
Analysis 220 
While we desisted from dichotomizing results of analyses purely on the basis of a P-221 
value into being ‘significant’ or not[29], as a means of grading the strength of evidence 222 
against the null hypothesis, in both the univariable and multivariable Mendelian 223 
randomization analyses, we used a two-sided alpha of 0.01, on the basis of testing 5 224 
lipid-related traits. Such a Bonferroni adjustment to account for multiple testing can be 225 
considered overly conservative given the high correlation between the lipid related 226 
traits.  227 
228 
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Results 229 
 230 
GWAS of blood lipid traits 231 
The lipid traits were measured in 393,193 to 440,546 individuals with GWAS genotyping 232 
(Table 1). On GWAS, we identified a large number of independent SNPs associated at 233 
P<5x10-8 with each lipid related trait: 220 SNPs (of which 56% had not been previously 234 
reported) associated with LDL cholesterol, 440 (77% novel) for triglycerides, 255 (80% 235 
novel) for apolipoprotein B, 534 (72% novel) for HDL cholesterol and 440 (93% novel) for 236 
apolipoprotein A-I (Figure 1 and Table 1). Full details of the SNPs associated with the 237 
lipid-related traits are provided in Supplementary Tables 1-5.  238 
 239 
A considerable number (477 out of a total 1044 clumped SNPs, i.e. 46%) of SNPs used in 240 
each of the lipid-related genetic instruments showed associations at conventional GWAS 241 
significance (P<5x10-8) with other lipid traits (Figure 2A). On exploring the relationships 242 
of the genetic instruments with each lipid-related trait, we identified widespread 243 
associations (Figure 2B). For example, in addition to its association with apolipoprotein 244 
B, the genetic instrument for apolipoprotein B showed strong positive associations with 245 
LDL cholesterol and triglycerides and inverse associations with HDL cholesterol and 246 
apolipoprotein A-I.  247 
 248 
Appraisal of LDL cholesterol, triglycerides and apolipoprotein B 249 
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On individual assessment through conventional MR, we identified LDL cholesterol, 250 
triglycerides and apolipoprotein B to have effect estimates consistent with a higher risk 251 
of CHD, using data from CARDIoGRAMplusC4D (with up to 60,801 cases) (Figure 3A). A 252 
1-SD higher LDL cholesterol had an OR of 1.66 (95%CI: 1.49; 1.86; P=2.4x10-19) for CHD 253 
with the corresponding value for triglycerides being (OR 1.34; 95%CI: 1.25, 1.44; 254 
P=9.1x10-16) and apolipoprotein B (OR 1.73; 95%CI: 1.56, 1.91; P=1.5x10-25). Sensitivity 255 
analyses using methodological approaches that take into account potential genetic 256 
pleiotropy led to no substantive change in these estimates (Supplementary Figure 2). 257 
 258 
When LDL cholesterol, triglycerides and apolipoprotein B were assessed together in 259 
multivariable MR, only apolipoprotein B (OR 1.92; 95%CI: 1.31, 2.81; P=7.5x10-4) 260 
retained a robust causal relationship with CHD (Figure 3A). The point estimate for LDL 261 
cholesterol reversed on mutual adjustment, to yield an adjusted OR of 0.85 (95%CI: 262 
0.57; 1.27; P=0.44). The estimate for triglycerides was weakened substantially (adjusted 263 
OR 1.12; 95%CI: 1.02, 1.23; P=0.01). 264 
 265 
Appraisal of HDL cholesterol and apolipoprotein A-I 266 
Individual analysis using conventional MR showed both HDL cholesterol and 267 
apolipoprotein A-I to have effect estimates consistent with a lower risk of CHD (Figure 268 
3B). The estimate for a 1-SD higher HDL cholesterol was OR 0.80 (95%CI: 0.75, 0.86; 269 
P=1.7x10-10) and for apolipoprotein A-I it was OR 0.83 (95%CI: 0.77, 0.89; P=9.96x10-7). 270 
The effect estimates for both HDL cholesterol and apolipoprotein A-I were diminished 271 
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when using methodologies that are more robust to potential pleiotropy of the genetic 272 
variants used in the analysis (Supplementary Figure 2).   273 
On appraisal in a multivariable MR analysis that included apolipoprotein B (which 274 
retained a causal relationship with CHD on mutual genetic adjustment for LDL 275 
cholesterol and triglycerides), the effect estimates of both HDL cholesterol and 276 
apolipoprotein A-I diminished and were not distinguishable from the null. (Figure 3B). 277 
The adjusted estimate for HDL-C was OR 0.91 (95%CI: 0.74, 1.12; P=0.36) and for 278 
apolipoprotein A-I it was OR 0.94 (95%CI: 0.76, 1.17; P=0.59). When adjusted for HDL 279 
cholesterol and apolipoprotein A-I, apolipoprotein B retained a robust causal effect on 280 
CHD (adjusted OR 1.68; 95%CI: 1.54, 1.84; P=6.5x10-32). 281 
 282 
The F-statistics for all lipid-related genetic instruments in both the univariable and 283 
multivariable MR settings were consistent with weak instruments being an unlikely 284 
source of bias (Table 1). 285 
 286 
287 
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Discussion 288 
 289 
Our study provides strong evidence from human genetics that supports apolipoprotein 290 
B being the underlying causal driver of the relationship of blood lipids and risk of CHD. 291 
This adds further evidence to support the hypothesis that it is the number of 292 
atherogenic lipoprotein particles, indexed by apolipoprotein B, rather than the amount 293 
of circulating cholesterol or triglycerides, that is the important driver of CHD[30]. In 294 
other words, changes in cholesterol or triglycerides that are not accompanied by 295 
commensurate changes in apolipoprotein B are unlikely to lead to altered risks of CHD. 296 
 297 
 298 
Our GWAS identified many hundreds of variants associated with the major lipid related 299 
traits, with most SNPs identified being novel. Many SNPs identified for one lipid-related 300 
trait also showed associations with other lipid traits, highlighting their pleiotropic 301 
nature. Individual appraisal using univariable Mendelian randomization showed 302 
widespread effects of all lipid-related traits, with LDL cholesterol, triglycerides and 303 
apolipoprotein B each having effect estimates consistent with a higher risk of CHD. 304 
These findings recapitulate those reported in previous studies [8, 9, 11, 12], leading to 305 
the contemporary view that each atherogenic lipid trait might play a causal role in 306 
vascular disease. When we estimated the direct (i.e. adjusted) effect of these traits 307 
using multivariable MR (see Supplementary Figure 1 for further details), only 308 
apolipoprotein B retained a robust causal effect with CHD, with the effect of LDL 309 
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cholesterol being reversed and that for triglycerides being largely diminished with only a 310 
very weak residual effect. The apparent protective associations of HDL cholesterol and 311 
apolipoprotein A-1, present on univariable MR analyses, were also markedly attenuated 312 
when direct effects conditional on apolipoprotein B were estimated. Taken together, 313 
these findings indicate that among the lipid related traits we investigated, it is 314 
apolipoprotein B, and thus the number of atherogenic lipoprotein particles, that 315 
predominates as the underlying cause of CHD. 316 
 317 
How do these findings enhance the evidence-base relating to lipid traits and vascular 318 
disease? Large-scale observational[31], interventional[4, 5] and genetic[6-9] studies 319 
support LDL cholesterol as being causal in the aetiology of CHD. In recent years, genetic 320 
studies have provided evidence in support of triglycerides[11, 12] also playing a causal 321 
role. Both LDL cholesterol and triglycerides are carried in atherogenic lipoproteins, each 322 
containing an apolipoprotein B particle. Recent narrative reviews[32] [33] point to 323 
apolipoprotein B potentially being the necessary entity for atherosclerosis to occur, for 324 
example, through the ‘response to retention’ hypothesis, in which apolipoprotein-B 325 
containing particles become trapped in the tunica intima of the arterial wall[34] .  Our 326 
study builds on recent findings[30] to provide further empirical evidence that supports 327 
this hypothesis, but our findings importantly do not discredit the causal roles that LDL 328 
cholesterol or triglycerides play in vascular disease. This is because apolipoprotein B 329 
does not occur in physiological circumstances in isolation[33], but rather is always 330 
accompanied by cholesterol and triglycerides. In light of this, our findings pinpoint that 331 
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it is apolipoprotein B that is necessary in order for atherogenesis to occur. Indeed, our 332 
findings from multivariable MR are consistent with apolipoprotein B being an essential 333 
element allowing the atherogenic effects of LDL cholesterol and triglyceride to be 334 
expressed. 335 
 336 
How do these findings aid us in the context of developing drugs that modify blood lipid 337 
concentrations and predicting their effects on risk of CHD? Drug-target Mendelian 338 
randomization studies show that, for example, modifying triglycerides through therapies 339 
such as ANGPLT3/4 inhibition may represent an emerging approach to lowering the risk 340 
of CHD[35-37] – do our findings contradict these data? Not so: our findings shed light on 341 
whether the concentrations of cholesterol and/or triglycerides that are carried by 342 
apolipoprotein B containing lipoproteins plays a role in CHD beyond that of 343 
apolipoprotein B. Based on these and recent data [13, 30], the primary focus of lipid 344 
modifying therapies ought to be the reduction in number of atherogenic lipoproteins (as 345 
measured by apolipoprotein B) rather than the reduction in cholesterol or triglycerides. 346 
This is especially the case where drugs have discrepant effects across these lipid 347 
traits.[10] [38] [13] Thus in predicting the vascular effects of a lipid-modifying 348 
therapeutic, apolipoprotein B can, all things being equal, be used as a reliable surrogate 349 
marker for the relative risk reduction in CHD – assuming, of course, that the drug under 350 
investigation does not display adverse events that arise either from target-mediated 351 
mechanisms, or off-target effects (notably, both can be measured directly, or 352 
extrapolated, from studies in human genetics[39]).  353 
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 354 
We note that this interpretation is in keeping with two important prior investigations 355 
that examined the concordance of CHD associations between SNPs associated with 356 
apolipoprotein B, LDL cholesterol[13] and triglycerides[30]. Indeed, one of these prior 357 
investigations conducted a form of multivariable MR analysis and obtained similar 358 
findings to those we report in the present study[30]. Importantly, the analysis that we 359 
conducted and report herein builds on these prior investigations by including the full 360 
repertoire of GWAS-associated SNPs for each of the lipid related traits (including a de 361 
novo GWAS of apolipoprotein B): such a comprehensive representation of trait-362 
associated SNPs is necessary in order to reliably interpret the MR estimates for each of 363 
the entities included in the multivariable MR analysis.  364 
 365 
The findings that we make have been made available by two recent advances. First, the 366 
availability of large-scale blood lipid phenotyping and GWAS genotyping in the UK 367 
Biobank, providing sufficiently large numbers to permit identification of robust genetic 368 
variants (and therefore suitable genetic instruments) in order to conduct MR of each of 369 
the lipid-related traits. Use of a single study with similar numbers of individuals with 370 
measures available for each lipid-related trait enabled GWAS and the downstream 371 
synthesis of genetic instruments for each trait in which the genetic architecture of each 372 
phenotype ought to be similarly represented, allowing for a more rigorous comparative 373 
assessment of the traits in both the univariable and multivariable MR setting. Second, 374 
methodological developments in MR to include more than one trait (so-called 375 
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multivariable MR) allows for “direct” effects (i.e. the effects of an exposure on disease, 376 
taking into account potential confounding and mediation by other traits) of multiple 377 
exposures to be assessed simultaneously and without the risk that this introduces forms 378 
of bias (such as collider bias)[15]. It is this methodological approach that allows the 379 
deduction that we make: that apolipoprotein B underlies the causal effects of lipid-380 
related traits with risk of CHD. We note here an important theme that emerges: the 381 
discrepancy between our findings and those derived from other MR approaches that 382 
hitherto have been used in contemporary MR studies (reflected by the univariable MR 383 
estimates we present in Supplementary Figure 2). While other approaches such as MR-384 
Egger and weighted median MR can provide reliable tests of causation even in the 385 
presence of confounding through unbalanced horizontal pleiotropy[40] (as evidenced by 386 
the diminution of the HDL cholesterol association with risk of CHD on MR-Egger, 387 
Supplementary Figure 2), such approaches notably do not, with a few exceptions [41, 388 
42], allow simultaneous statistical adjustment for multiple traits. The repertoire of 389 
univariable MR analyses that seek to act as sensitivity analyses for potential pleiotropy 390 
each makes a different series of assumptions [22]. In the context that genetic 391 
confounding affects the majority of SNPs used in the genetic instruments, and when 392 
such confounding is present in a dose-response manner (i.e. on average, SNPs that 393 
increase the exposure of interest also increase the confounder of interest), this violates 394 
the ‘inSIDE’ assumption[24] and the MR analyses yield biased estimates. This is why the 395 
MR estimates for LDL cholesterol and triglycerides remain seemingly robust to MR Egger 396 
and weighted median MR approaches. In this context, multivariable MR analysis can 397 
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help when the traits included in the analysis account fully for the unbalanced, dose-398 
related, horizontal pleiotropy. In the scenario that we investigate, apolipoprotein B does 399 
just so, permitting us to conclude that it is apolipoprotein B that is ultimately 400 
responsible for the underlying causal relationship of blood lipids and risk of CHD. 401 
 402 
In conclusion, our findings demonstrate that apolipoprotein B underlies the causal effect 403 
of lipids on CHD and that it is the trait that is responsible for the associations of LDL 404 
cholesterol, triglycerides, HDL cholesterol and apolipoprotein A-I with the risk of CHD. 405 
 406 
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 Table 1. Genetic variants identified for each trait in UK Biobank. 
 
* We defined novel SNPs as those associated with the trait of interest at P<5x10-8 where an 
association had not been previously reported at P<5x10-8, within 1MB and at r2<0.001 by the 
Global Lipids Genetics Consortium[20] (for LDL cholesterol, triglycerides and HDL cholesterol) or 
by Kettunen et al[21] (for apolipoprotein B or apolipoprotein A-I). 
^ The conditional F-statistic for apolipoprotein B when included in the multivariable MR model 
with LDL cholesterol and triglycerides was 36, and in the multivariable MR model that included 
HDL cholesterol and apolipoprotein A-I it was 66. 
 
 
 
 
 
Trait Number 
with trait 
measured in 
UK Biobank 
with GWAS 
genotyping 
Number of 
SNPs 
identified 
in GWAS 
(P<5x10-8) 
Number 
(%) of 
novel* 
SNPs 
Number (%) of 
SNPs aligned 
to 
CARDIoGRAM-
plusC4D 
F-statistic 
overall and 
conditional 
LDL cholesterol 440,546 220 123 (56%) 209 (95%) 164, 34 
Triglycerides 441,016 440 339 (77%) 409 (93%) 116, 78 
Apolipoprotein B 439,214 255 203 (80%) 234 (92%) 153, 36^ 
HDL cholesterol 403,943 534 383 (72%) 490 (92%) 124, 67 
Apolipoprotein A-I 393,193 440 407 (93%) 407 (93%) 120, 62 
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Figure 1. Manhattan plots showing findings from GWAS of lipid-related traits in UK Biobank 
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Figure 2. Characteristics of genetic instruments developed for lipid-related traits: (A) overlap of SNPs and (B) associations with 
lipids and apolipoproteins                                                                                                                                           
  (A)                                                                                                                   
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(B) 
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Legend: In Panel A, SNPs are grouped according to whether they associate with only the primary lipid-related trait of interest, or whether they 
associate with other traits, based on P<5x10-8. Panel B displays the associations of genetic instruments with lipid related traits, using the inverse 
variance weighting approach. While we note the potential for overfitting of estimates displayed in Panel B, we present these data for illustrative 
purposes; the Mendelian randomization estimates presented in Figure 3 use a two-sample approach (with no overlapping data). 
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Figure 3. Univariable and multivariable Mendelian randomization of so-called (A) 
atherogenic and (B) protective lipids and apolipoproteins and risk of CHD. 
 
(A) 
 
 
(B) 
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Legend: In both (A) and (B), univariable Mendelian randomization (MR) estimates were derived using 
the inverse variance weighted approach. For a more comprehensive repertoire of estimates derived 
from univariable MR approaches, please see Supplementary Figure 2. 
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